Ultime notizie per McKesson (NYSE:MCK) Azioni

McKesson

McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

RIVN

Scopri i 5 titoli da seguire oggi, 7 agosto 2024, con un focus particolare su McKesson, Wix, Disney, Rivian e CVS.

Pre-market: 5 titoli da monitorare oggi, 7 agosto 2024

McKesson Corp

MALLINCKRODT PB LTD CO by Mallinckrodt plc.

Mallinckrodt PLC

Jade Leader Corp

MCKESSON ORD

McKesson Europe AG ADR

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 15 years by 3.02% on an annualized basis producing an average annual return of 15.04%. Currently, McKesson has a market capitalization of $61.95 billion. 
Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 15 years ago, it would be worth $8,020.07 today based on a price of $477.60 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727287225_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning McKesson Stock In The Last 15 Years

Deutsche Bank analyst George Hill maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Buy and lowers the price target from $623 to $579.

Price Target

Analyst Ratings

Deutsche Bank Maintains Buy on McKesson, Lowers Price Target to $579

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often <a href="https://www.benzinga.com/24/04/38333549/jim-cramer-is-willing-to-let-this-pharma-stock-catch-fire-advises-not-to-sell-mckesson">experience a rally.</a>
After a rapid move lower, shares of McKesson Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>)have become oversold. They have also reached a price level that may provide support. This is why our team of trading experts has made it our Stock of the Day.
The red line on the chart below is called a Bollinger Band. It is two standard deviations below the 20-day moving average.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24132418/mck-chart-1024x628.png" alt="" class="wp-image-563894" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24132418/mck-chart-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24132418/mck-chart-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24132418/mck-chart-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24132418/mck-chart.png 1183w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
According to statistics and probability theory, 95% of trading should occur within two standard deviations of the mean or average. If this threshold is exceeded to the downside, the stock is considered to be oversold. This could draw buyers into the market.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/09/40844961/mckesson-rises-yet-lags-behind-market-some-facts-worth-knowing">McKesson Rises Yet Lags Behind Market: Some Facts Worth Knowing</a>
They will be expecting a reversion to the mean or a move higher. Their buying could push the price upwards. As you can see on the chart, over the past year, every time McKesson fell below the Bollinger Band, a move higher followed.
The stock is also trading at a price level that may act as support. The $472 level was resistance at the end of last year. Price levels that were previously resistance tend to turn into support.
This is a common occurrence in the financial markets. It happens because of remorseful sellers.
Some traders and investors sold while the shares were at resistance and regretted doing so when the price moved higher. A number of these disappointed sellers decided to buy their shares back.
But they will only do so if they can buy them at the same price they were sold. As a result, when the stock eventually returns to their selling price, they place buy orders. If there are enough of these buy orders, it will create support at the price that had previously been resistance.
Stocks that are oversold and at support tend to rally. There's a good chance that this will be the case with <a href="https://www.benzinga.com/quote/MCK">McKesson</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/09/41007724/gold-breaks-records-on-chinas-policy-stimulus-mining-metal-stocks-exhibit-strongest-1-day-rally-in-2">Gold Breaks Records On China&#8217;s Policy Stimulus: Mining, Metal Stocks Exhibit Strongest 1-Day Rally In 2024</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Technicals

Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?

WIIM

McKesson shares are trading lower after Baird downgraded the stock from Outperform to Neutral and lowered its price target from $603 to $531.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Redburn Atlantic raised the price target for Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) from $119 to $120. Redburn Atlantic analyst Peter Low downgraded the stock from Buy to Neutral. Exxon Mobil shares rose 1.8% to close at $117.36 on Monday. <a href="https://www.benzinga.com/quote/xom/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased the price target for Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) from $15 to $16.5. Needham analyst John Todaro maintained a Buy rating. Hut 8 shares gained 3.6% to close at $11.57 on Monday. <a href="https://www.benzinga.com/quote/hut/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $603 to $531. Baird analyst Eric Coldwell downgraded the stock from Outperform to Neutral. McKesson shares fell 0.6% to close at $505.00 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/mck/analyst-ratings">how </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">other analysts view this stock</a>.</li>
<li>Morgan Stanley raised BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) price target from $93 to $145. Morgan Stanley analyst Terence Flynn upgraded the stock from Equal-Weight to Overweight. BioNTech shares gained 0.7% to close at $113.05 on Monday. <a href="https://www.benzinga.com/quote/bntx/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this </a><a href="https://www.benzinga.com/quote/bntx/analyst-ratings">stock</a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">.</a></li>
<li>Wedbush raised Banc of California, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) price target from $14 to $18. Wedbush analyst David Chiaverini upgraded the stock from Neutral to Outperform. Banc of California shares fell 1.4% to close at $14.84 on Monday. <a href="https://www.benzinga.com/quote/banc/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this </a><a href="https://www.benzinga.com/quote/banc/analyst-ratings">stock</a>.</li>
<li>Morgan Stanley cut the price target for Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) from $45 to $41. Morgan Stanley analyst Brian Nowak maintained an Equal-Weight rating. Maplebear fell 4.6% to close at $40.22 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/cart/analyst-ratings">how other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock</a>.</li>
<li>Wedbush raised Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) price target from $52 to $75. Wedbush analyst David Chiaverini upgraded the stock from Neutral to Outperform. Comerica shares fell 2.1% to close at $60.20 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See</a><a href="https://www.benzinga.com/quote/cma/analyst-ratings"> how </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">other analysts view this stock</a>.</li>
<li>Piper Sandler cut the price target for Celsius Holdings, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) from $50 to $47. Piper Sandler analyst Michael Lavery maintained an Overweight rating. Celsius shares fell 1.1% to close at $32.80 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how </a><a href="https://www.benzinga.com/quote/celh/analyst-ratings">other analysts </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">view this stock</a>.</li>
<li>Oppenheimer cut Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) price target from $60 to $51. Oppenheimer analyst Brian Schwartz maintained an Outperform rating. Braze shares fell 4.9% to close at $34.62 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/brze/analyst-ratings">how </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">other </a><a href="https://www.benzinga.com/quote/brze/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">view this stock</a>.</li>
<li>Susquehanna slashed Light &amp; Wonder, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNW#NASDAQ">LNW</a>) price target from $92 to $90. Susquehanna analyst Joseph Stauff maintained a Neutral rating. Light &amp; Wonder shares gained 0.1% to close at $112.68 on Monday. <a href="https://www.benzinga.com/quote/lnw/analyst-ratings">See how other </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analysts view this stock</a>.</li>
</ul>
Considering buying XOM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="519" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24084729/image-189-1024x519.png" alt="" class="wp-image-563133" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24084729/image-189-1024x519.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24084729/image-189-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24084729/image-189-768x389.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/24084729/image-189.png 1326w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41000017/how-to-earn-500-a-month-from-nvidia-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41000017/how-to-earn-500-a-month-from-nvidia-stock">How To Earn $500 A Month From Nvidia Stock</a></li>
</ul>

BANC

BNTX

BRZE

CART

CELH

Exxon Mobil To $120? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://widgets.benzinga.com/analyst-stock-ratings/analyst/60f00f67c9514d0001c5b305/charlene-liu">HSBC analyst Charlene Liu</a> downgraded the rating for Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) from Buy to Hold and announced a price target of $100. Baidu shares gained 2.4% to close at $88.28 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other </a><a href="https://www.benzinga.com/quote/bidu/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">view this stock</a>.</li>
<li>Redburn Atlantic analyst Peter Low downgraded the rating for BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) from Buy to Neutral. BP shares gained 0.7% to close at $32.86 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this </a><a href="https://www.benzinga.com/quote/BP/analyst-ratings">stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell </a>downgraded McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Outperform to Neutral and lowered the price target from $603 to $531. McKesson shares fell 0.6% to close at $505.00 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See</a><a href="https://www.benzinga.com/quote/MCK/analyst-ratings"> </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Andrew Berens downgraded the rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) from Outperform to Market Perform, while cutting the price target from $1,175 to $1,077. Regeneron Pharmaceuticals shares fell 4.6% to close at $1,091.98 on Monday. <a href="https://www.benzinga.com/quote/REGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59c264af6e84a70001eb1bb8/david-chiaverini">Wedbush analyst David Chiaverini </a>downgraded First Horizon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) from Outperform to Neutral and slashed the price target from $20 to $17. First Horizon shares fell 1.9% to close at $15.67 on Monday. <a href="https://www.benzinga.com/quote/FHN/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock</a>.</li>
</ul>
Considering buying BP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/c9689ca0-032e-42a9-818e-8c799d42f940" alt="" style="width:618px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40991631/jim-cramer-says-this-utilities-stock-is-a-buy-we-need-cheap-power">Jim Cramer Says This Utilities Stock Is A Buy: &#8216;We Need Cheap Power&#8217;</a></li>
</ul>

Downgrades

BIDU

REGN

This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Baird analyst Eric Coldwell downgrades McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Outperform to Neutral and lowers the price target from $603 to $531.

Baird Downgrades McKesson to Neutral, Lowers Price Target to $531

Investors with significant funds have taken a bullish position in McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in MCK usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 12 options transactions for McKesson. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 58% being bullish and 25% bearish. Of all the options we discovered, 11 are puts, valued at $743,330, and there was a single call, worth $40,950.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $550.0 for McKesson over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for McKesson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of McKesson's whale trades within a strike price range from $500.0 to $550.0 in the last 30 days. 
<h3>McKesson Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726843559_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$45.1</td>
<td>$43.2</td>
<td>$43.2</td>
<td>$550.00</td>
<td>$203.0K</td>
<td style="text-align: right;">256</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$9.8</td>
<td>$6.6</td>
<td>$9.0</td>
<td>$500.00</td>
<td>$121.5K</td>
<td style="text-align: right;">648</td>
<td style="text-align: right;">358</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$7.4</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$500.00</td>
<td>$53.9K</td>
<td style="text-align: right;">648</td>
<td style="text-align: right;">121</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$45.5</td>
<td>$41.4</td>
<td>$43.8</td>
<td>$550.00</td>
<td>$52.5K</td>
<td style="text-align: right;">256</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$45.2</td>
<td>$43.7</td>
<td>$43.7</td>
<td>$550.00</td>
<td>$48.0K</td>
<td style="text-align: right;">256</td>
<td style="text-align: right;">55</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
<h3>Present Market Standing of McKesson</h3>
<ul>
<li>Currently trading with a volume of 246,110, the MCK's price is down by -0.55%, now at $505.38. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 40 days.</li>
</ul>
<h3>Expert Opinions on McKesson</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $610.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on McKesson, which currently sits at a price target of $535. 
&#x2A; An analyst from Leerink Partners persists with their Outperform rating on McKesson, maintaining a target price of $665. 
&#x2A; An analyst from Citigroup persists with their Buy rating on McKesson, maintaining a target price of $630. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for McKesson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Spotlight on McKesson: Analyzing the Surge in Options Activity

Wells Fargo analyst Stephen Baxter maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Equal-Weight and lowers the price target from $576 to $535.

Wells Fargo Maintains Equal-Weight on McKesson, Lowers Price Target to $535

The most recent trading session ended with McKesson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>) standing at $511.17, reflecting a +0.14% shift from the previouse trading day&#39;s closing. This change lagged the S&amp;P 500&#39;s 0.75% gain on the day. Elsewhere, the Dow saw an upswing of 0.58%, while the tech-heavy Nasdaq appreciated by 1%.
The prescription drug distributor&#39;s shares have seen a decrease of 7.67% over the last month, not keeping up with the Medical sector&#39;s gain of 3.55% and the S&amp;P 500&#39;s gain of 4.03%.
The investment community will be paying close attention to the earnings performance of McKesson in its upcoming release. It is anticipated that the company will report an EPS of $7.20, marking a 15.57% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $89.57 billion, up 16% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $32.11 per share and a revenue of $353.29 billion, signifying shifts of +17.02% and +14.35%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for McKesson. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts&#39; positivity towards the company&#39;s business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 2.25% higher within the past month. At present, McKesson boasts a Zacks Rank of #3 (Hold).
With respect to valuation, McKesson is currently being traded at a Forward P/E ratio of 15.9. This represents a discount compared to its industry&#39;s average Forward P/E of 18.11.
We can also see that MCK currently has a PEG ratio of 1.18. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company&#39;s expected earnings growth trajectory. The average PEG ratio for the Medical - Dental Supplies industry stood at 1.88 at the close of the market yesterday.
The Medical - Dental Supplies industry is part of the Medical sector. With its current Zacks Industry Rank of 176, this industry ranks in the bottom 31% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
<a href="https://www.zacks.com/stock/news/2335566/mckesson-mck-rises-yet-lags-behind-market-some-facts-worth-knowing?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_6v2-2335566">To read this article on Zacks.com click here.</a>

Large Cap

Health Care

General

McKesson Rises Yet Lags Behind Market: Some Facts Worth Knowing

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 20 years by 7.5% on an annualized basis producing an average annual return of 15.73%. Currently, McKesson has a market capitalization of $65.81 billion. 
Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 20 years ago, it would be worth $18,461.59 today based on a price of $507.35 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726074017_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning McKesson Stock In The Last 20 Years

Deep-pocketed investors have adopted a bullish approach towards McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MCK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for McKesson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 45% bearish. Among these notable options, 3 are puts, totaling $420,700, and 8 are calls, amounting to $1,234,640.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $510.0 to $540.0 for McKesson over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for McKesson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of McKesson's whale trades within a strike price range from $510.0 to $540.0 in the last 30 days. 
<h3>McKesson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725991274_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$9.2</td>
<td>$8.7</td>
<td>$8.8</td>
<td>$530.00</td>
<td>$352.5K</td>
<td style="text-align: right;">110</td>
<td>808</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$34.3</td>
<td>$33.2</td>
<td>$33.2</td>
<td>$520.00</td>
<td>$251.8K</td>
<td style="text-align: right;">1</td>
<td>76</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$7.2</td>
<td>$6.4</td>
<td>$7.0</td>
<td>$530.00</td>
<td>$208.4K</td>
<td style="text-align: right;">110</td>
<td>300</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$6.8</td>
<td>$6.3</td>
<td>$6.7</td>
<td>$530.00</td>
<td>$165.9K</td>
<td style="text-align: right;">110</td>
<td>1.1K</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$29.9</td>
<td>$27.5</td>
<td>$29.2</td>
<td>$540.00</td>
<td>$146.0K</td>
<td style="text-align: right;">152</td>
<td>51</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Following our analysis of the options activities associated with McKesson, we pivot to a closer look at the company's own performance.
<h3>McKesson's Current Market Status</h3>
<ul>
<li>With a trading volume of 525,664, the price of MCK is down by -0.31%, reaching $507.85.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for McKesson</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $652.0.
<ul>
<li>Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on McKesson with a target price of $630. </li>
<li>Maintaining their stance, an analyst from Leerink Partners continues to hold a Outperform rating for McKesson, targeting a price of $665. </li>
<li>Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on McKesson with a target price of $661. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for McKesson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On McKesson

Citigroup analyst Daniel Grosslight maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Buy and lowers the price target from $670 to $630.

Citigroup Maintains Buy on McKesson, Lowers Price Target to $630

<a href="http://biologics.mckesson.com/">Biologics by McKesson</a>, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Geron Corporation as a limited specialty pharmacy provider for RYTELOTM (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, &nbsp;have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESA).
RYTELO, approved by the U.S. Food and Drug Administration (FDA) on June 6, 2024, is a first-in-class telomerase inhibitor. RYTELO binds to the template region of the RNA component of human telomerase (hTR), inhibiting telomerase enzymatic activity and preventing telomere binding.1 Increased telomerase activity has been reported in MDS malignant stem and progenitor cells. &nbsp;&nbsp;

Biotech

Biologics by McKesson's RYTELOTM, FDA Gets Approval For Treatment Of Patients With Low- To Intermediate-1 Risk Myelodysplastic Syndromes  With Transfusion-Dependent Anemia

The Nasdaq 100 closed lower by over 500 points during Friday's session. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Microsoft</h3>
<ul>
<li>The Trade: Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) EVP, CFO Amy Hood <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 40,450 shares</a> at an average price of $410.55. The insider received around $15.6 million from selling those shares.</li>
<li>What's Happening: Microsoft Corp recently launched a new line of Windows PCs with AI capabilities.</li>
<li>What Microsoft Does: Microsoft develops and licenses consumer and enterprise software.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"> latest MSFT news. </a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="907" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09074623/image-68.png" alt="" class="wp-image-537138" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09074623/image-68.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09074623/image-68-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09074623/image-68-768x704.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></figure>
<h3 class="wp-block-heading">McKesson</h3>
<ul>
<li>The Trade: McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) CEO Brian S. Tyler sold a total of 3,753 shares at an average price of $561.10. The insider received around $2.11 million from selling those shares.</li>
<li>What's Happening: McKesson, last week, signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners.</li>
<li>What McKesson Does: McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1">trend in MCK stock. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09052922/image-1-16.png" alt="" class="wp-image-536858" style="width:657px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09052922/image-1-16.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09052922/image-1-16-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09052922/image-1-16-768x712.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">News Corporation</h3>
<ul>
<li>The Trade: News Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>) Chief Technology Officer David R Kline <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 10,000 shares</a> at an average price of $26.96. The insider received around $269,626 from selling those shares.</li>
<li>What's Happening: On Aug. 8, News Corporation reported better-than-expected fourth-quarter financial results.</li>
<li>What News Corporation Does: News Corporation is a diversified media conglomerate with significant presence in the us, the UK, and Australia. </li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1">breakout in NWSA shares. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053038/image-63.png" alt="" class="wp-image-536860" style="width:650px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053038/image-63.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053038/image-63-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053038/image-63-768x725.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
<h3 class="wp-block-heading">Fluor</h3>
<ul>
<li>The Trade: Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) EVP, CFO Joseph L Brennan sold a total of 31,260 shares at an average price of $46.65. The insider received around $1.46 million from selling those shares.</li>
<li>What's Happening: On Aug. 2, Fluor reported second-quarter fiscal 2024 revenue growth of 7.3% year over year to $4.227 billion, missing the consensus of $4.360 billion.</li>
<li>What Fluor Does: Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. </li>
<li>Benzinga Pro's earnings calendar was used to track upcoming <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1">FLR&#8217;s earnings reports. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="888" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053132/image-64.png" alt="" class="wp-image-536861" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053132/image-64.png 888w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053132/image-64-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09053132/image-64-768x720.png 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40767657/s-p-500-records-largest-weekly-decline-since-march-2023-as-nvidia-google-tumble-fear-greed-index">S&amp;P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear &amp; Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

Short Ideas

Insider Trades

MSFT

NWSA

McKesson, News Corporation And 2 Other Stocks Executives Are Selling

Leerink Partners analyst Michael Cherny maintains McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) with a Outperform and lowers the price target from $670 to $665.

Leerink Partners Maintains Outperform on McKesson, Lowers Price Target to $665

Guidance

McKesson Sees Q2 Fiscal 2025 Adj EPS To Be In Range Of $6.70-$7.00 Vs $7.39 Est.; Reaffirms FY25 Adj EPS Guidance In Range Of $31.75-$32.55 Vs $32.21 Est.

Investors with a lot of money to spend have taken a bearish stance on McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for McKesson.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 58%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $872,070, and 3 are calls, for a total amount of $329,936.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $570.0 for McKesson over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in McKesson's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to McKesson's substantial trades, within a strike price spectrum from $300.0 to $570.0 over the preceding 30 days.
<h3>McKesson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725549397_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$53.9</td>
<td>$49.7</td>
<td>$50.7</td>
<td>$570.00</td>
<td>$248.4K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">125</td>
</tr>
<tr>
<td>MCK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$253.0</td>
<td>$248.0</td>
<td>$248.0</td>
<td>$300.00</td>
<td>$248.0K</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$9.0</td>
<td>$5.4</td>
<td>$4.9</td>
<td>$500.00</td>
<td>$245.0K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">506</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$52.9</td>
<td>$49.0</td>
<td>$50.7</td>
<td>$570.00</td>
<td>$157.1K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">73</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$51.0</td>
<td>$48.3</td>
<td>$51.0</td>
<td>$570.00</td>
<td>$56.1K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">34</td>
</tr>
</tbody>
</table>

<h3>About McKesson</h3>
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Following our analysis of the options activities associated with McKesson, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of McKesson</h3>
<ul>
<li>With a volume of 805,632, the price of MCK is down -1.97% at $560.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 55 days.</li>
</ul>
<h3>What The Experts Say On McKesson</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $644.5.
<ul>
<li>Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for McKesson, targeting a price of $630. </li>
<li>An analyst from Barclays persists with their Overweight rating on McKesson, maintaining a target price of $616. </li>
<li>An analyst from JP Morgan persists with their Overweight rating on McKesson, maintaining a target price of $661. </li>
<li>An analyst from Baird persists with their Outperform rating on McKesson, maintaining a target price of $671. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McKesson, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding McKesson's Options Activity: What's the Big Picture?

McKesson shares are trading lower after the company announced it signed  an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners.

McKesson Canada will continue to own and operate Rexall and Well.ca until transaction close, which is subject to customary closing conditions, including necessary regulatory clearances.
In line with McKesson Corporation&#39;s enterprise strategy, this transaction enables McKesson to further focus and prioritize investments to grow its oncology and biopharma services platforms.&nbsp;

Asset Sales

McKesson Agrees To Sell Its Canada-based Rexall And Well.ca Businesses To Birch Hill Equity Partners; No Terms Disclosed

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX – Research Report), McKesson (MC...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)

Leerink Partners analyst Michael Cherny has reiterated their bullish stance on MCK stock, giving a Buy rating on September 10. Michael Cherny has g...

Michael Cherny Reaffirms Buy Rating on McKesson Amid Temporary Setbacks and Long-Term Growth Prospects

Cardinal Health Inc. is one of the leading wholesale distributors of pharmaceuticals, medical/surgical supplies and related products to a broad range of health care customers.

Cardinal Health, Inc. Dividend Stock Analysis

McKesson - Meet The New Dividend Stock On My Watchlist

Robert W. Baird analyst Eric Coldwell downgraded the rating on McKesson (MCK – Research Report) to a Hold today, setting a price target of $531.00....

McKesson: Operational and Strategic Challenges Prompt Hold Rating

McKesson cut to Neutral at Baird on "unusual" sell side event

Tracking Lone Pine Capital Portfolio - Q2 2024 Update

Analyst Michael Cherny of Leerink Partners maintained a Buy rating on McKesson (MCK – Research Report), retaining the price target of $665.00. Mich...

Buy Rating Affirmed: McKesson's Long-term Growth Strategy Balances Short-term Earnings Concerns

Deutsche Bank analyst George Hill maintained a Buy rating on McKesson (MCK – Research Report) today and set a price target of $579.00. George Hill ...

Buy Rating Affirmed: McKesson's Growth and Earnings Potential Amidst Investor Concerns

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

AMZN

ARES

ASML

ASMLF

AVDX

BBWI

BKNG

BPOP

BSQKZ

CADE

CFFI

CHCO

CHRW

CMCSA

CSCO

CTBI

CUBE

EPAM

ERIE

FFIN

FISI

FMAO

FULT

FUNC

GAIN

HBNC

HLNE

HWBK

IMRX

INDB

INGR

INTU

LPLA

LRCX

MBIN

MORN

NBIX

RGLD

SCVL

SFBS

SFNC

SPOT

SPTN

SWBI

SYBT

THFF

TSMWF

UBSI

UMBF

UTMD

VICI

WASH

WDAY

WSBC

Press Releases

McKesson Corporation Announces Fourth Quarter Fiscal 2024 Earnings Release Date

McKesson Corporation Declares Quarterly Dividend

McKesson Corporation Reports Fiscal 2024 Fourth Quarter and Full Year Results

McKesson's Board of Directors Elects Deborah Dunsire as New Director

McKesson Corporation Announces First Quarter Fiscal 2025 Earnings Release Date

McKesson Raises Quarterly Dividend by 15% to $0.71 Per Share

McKesson Corporation Reports Fiscal 2025 First Quarter Results

McKesson Signs Agreement to Acquire Controlling Interest in Florida Cancer Specialists & Research Institute's Core Ventures

McKesson Corporation Announces Sale of Rexall and Well.ca Businesses to Birch Hill Equity Partners

Comments

McKesson

Notizie

Ultime notizie per McKesson (NYSE:MCK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO